Tirzepatide (Mounjaro/Zepbound): Complete Guide to Dosing, Results, and Side Effects

Medici

29 Apr 2026 — 6 min read

Tirzepatide is one of the most significant advances in obesity and diabetes treatment in decades. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, it works through a unique dual-receptor mechanism that produces greater weight loss than any previously approved medication. In head-to-head trials, it outperformed semaglutide (Wegovy) by nearly 50% in relative weight reduction.

This guide covers everything: how tirzepatide works, Mounjaro vs Zepbound differences, the dosing schedule, what to expect in terms of results, side effects, cardiovascular benefits, how it compares to semaglutide, and the current legal status of compounded tirzepatide in 2026.

What Is Tirzepatide?

Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly. It is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist — often called a "twincretin" because it activates two incretin hormone receptors simultaneously.

The FDA approved tirzepatide in two separate formulations:

Mounjaro (tirzepatide) — approved May 2022 for type 2 diabetes management
Zepbound (tirzepatide) — approved November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition

Both contain the exact same active molecule at the same doses. The difference is brand packaging, pricing structure, and the approved indication.

How Tirzepatide Works: The Dual GIP/GLP-1 Mechanism

To understand why tirzepatide is more effective than earlier GLP-1 medications, you need to understand what GIP adds to the equation.

GLP-1 receptor activation suppresses appetite by acting on hunger centers in the hypothalamus, slows gastric emptying so you feel full longer, and stimulates insulin secretion in a glucose-dependent manner (meaning it only triggers insulin when blood sugar is elevated — reducing hypoglycemia risk).

GIP receptor activation works on adipose (fat) tissue to regulate lipid uptake and storage, enhances insulin sensitivity in muscle and fat cells, and may reduce the nausea that often accompanies pure GLP-1 agonism. When GIP and GLP-1 are activated simultaneously, the effects on fat metabolism and energy expenditure appear to be synergistic — greater than either would produce alone.

This dual mechanism is why tirzepatide achieves substantially greater weight loss than semaglutide, which activates only the GLP-1 receptor.

Mounjaro vs Zepbound: What's the Difference?

Patients and prescribers are often confused about why the same drug has two names. Here's the practical breakdown:

Mounjaro is prescribed for type 2 diabetes. Insurance coverage under diabetes benefits is typically more favorable, and it's been available longer.
Zepbound is prescribed for obesity/weight loss. Insurance coverage is more variable and depends on whether a plan includes anti-obesity medication (AOM) benefits.

Clinically, both deliver identical tirzepatide at the same doses. Some patients with diabetes are prescribed Mounjaro and experience significant weight loss — a common off-label benefit that ultimately drove Lilly to pursue and receive Zepbound's separate obesity approval.

Tirzepatide Dosing Schedule

Tirzepatide is administered as a subcutaneous injection once weekly — typically in the abdomen, thigh, or upper arm. The dose escalation schedule is designed to minimize gastrointestinal side effects during initiation:

Weeks 1–4: 2.5 mg once weekly (initiation dose only — not a maintenance dose)
Weeks 5–8: 5 mg once weekly
Weeks 9–12: 7.5 mg once weekly (if additional glycemic/weight control is needed)
Weeks 13–16: 10 mg once weekly
Weeks 17–20: 12.5 mg once weekly
Week 21+: 15 mg once weekly (maximum approved dose)

Doses can be increased in 2.5 mg increments no more frequently than every 4 weeks. If a dose increase causes intolerable side effects, the prescriber may hold at the current dose longer before escalating. Most patients reach a maintenance dose somewhere between 10–15 mg depending on their tolerance and response.

Clinical Results: How Much Weight Loss to Expect

Tirzepatide's weight loss results in clinical trials are the most impressive of any approved obesity medication to date.

SURMOUNT-1 Trial (72 weeks, non-diabetic patients with obesity)

5 mg dose: average weight loss of 15.0%
10 mg dose: average weight loss of 19.5%
15 mg dose: average weight loss of 20.9%
Placebo: average weight loss of 3.1%

At the 15 mg dose, 1 in 3 participants lost 25% or more of their body weight — entering territory previously only seen with bariatric surgery.

SURMOUNT-1 Long-Term: Cardiovascular Risk Reduction (176 Weeks)

A post-hoc analysis of 3-year SURMOUNT-1 data found that tirzepatide significantly reduced 10-year predicted cardiovascular disease risk compared to placebo. Using the ACC/AHA risk calculator, the 15 mg dose produced a 9.2% relative reduction in predicted ASCVD risk. The 15 mg dose also reduced predicted 10-year type 2 diabetes risk — a critical finding given that over 70% of obese adults are at elevated risk.

SURPASS-CVOT: Cardiovascular Outcomes in Type 2 Diabetes

The SURPASS-CVOT trial compared tirzepatide to dulaglutide (another GLP-1 agonist) in patients with type 2 diabetes and established cardiovascular disease. Over a median 4-year follow-up, the primary endpoint — death from cardiovascular causes, MI, or stroke — occurred in 12.2% of tirzepatide patients vs. 13.1% for dulaglutide. Tirzepatide met its non-inferiority endpoint and showed trends toward superiority.

Tirzepatide vs Semaglutide: Head-to-Head Results

The SURMOUNT-5 trial provided the first direct, randomized head-to-head comparison between tirzepatide (Zepbound) and semaglutide (Wegovy) in adults with obesity but without type 2 diabetes. The results were decisive:

Tirzepatide (up to 15 mg): 20.2% average weight loss
Semaglutide (up to 2.4 mg): 13.7% average weight loss
Tirzepatide produced 47% greater relative weight loss

This superiority was consistent across all subgroups — regardless of sex, age, baseline BMI, or the presence of metabolic comorbidities. Multiple meta-analyses and real-world dataset analyses published in 2025–2026 have confirmed tirzepatide's advantage in both absolute and relative weight reduction.

That said, semaglutide remains a highly effective treatment. A 13.7% average weight loss represents a major, clinically meaningful outcome. The choice between them often comes down to availability, insurance coverage, side effect tolerance, and individual response.

Side Effects and Safety Profile

Tirzepatide is generally well tolerated. The most common side effects are gastrointestinal and are most pronounced during dose escalation:

Common side effects (>5% of patients)

Nausea (the most frequent complaint, especially at initiation)
Diarrhea
Vomiting
Constipation
Decreased appetite (desired in weight loss context)
Abdominal discomfort / dyspepsia

GI side effects typically diminish after the first few weeks on each dose level. Slower up-titration and taking doses with food can help.

Serious but less common side effects

Pancreatitis: Rare but serious. Discontinue and seek care immediately for severe upper abdominal pain radiating to the back.
Gallbladder disease: Gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis) occur at higher rates with rapid weight loss. Increased compared to placebo in trials.
Thyroid C-cell tumors: Observed in rodent studies (as with all GLP-1 agonists). Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
Hypoglycemia: Low risk in non-diabetics due to glucose-dependent mechanism; higher risk in T2D patients using concurrent insulin or sulfonylureas.
Muscle loss: A concern with any rapid weight loss. Adequate protein intake and resistance training are recommended during treatment.

Discontinuation rates due to GI side effects ranged from 3.3% at the 10 mg dose to 4.3% at the 15 mg dose in Zepbound trials — vs 0.5% on placebo.

Who Should Consider Tirzepatide?

Tirzepatide is FDA-approved for:

Adults with type 2 diabetes (as an adjunct to diet and exercise)
Adults with obesity (BMI ≥30 kg/m²)
Adults with overweight (BMI ≥27 kg/m²) who also have at least one weight-related condition such as hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease

Contraindications include:

Personal or family history of medullary thyroid carcinoma
Multiple endocrine neoplasia syndrome type 2 (MEN2)
Pregnancy (weight-loss medications are not appropriate during pregnancy)
Known hypersensitivity to tirzepatide or any excipient

Compounded Tirzepatide in 2026: What You Need to Know

During the tirzepatide shortage period (2023–2024), the FDA placed tirzepatide on the drug shortage list, which allowed 503A compounding pharmacies to legally produce compounded versions. This created a large market for lower-cost compounded tirzepatide.

In March 2025, the FDA declared the tirzepatide shortage resolved and ended enforcement discretion for 503A compounding pharmacies. This is a significant regulatory shift:

503A pharmacies (state-licensed retail compounders): Cannot legally produce compounded tirzepatide in 2026 except in narrow documented cases — specifically, when a patient has a verified allergy to an inactive ingredient in the brand-name product that cannot otherwise be accommodated.
503B outsourcing facilities (large-scale compounders): Similarly restricted following the shortage resolution. FDA enforcement discretion for 503B also ended in March 2025.

Courts have largely sided with the FDA in legal challenges brought by compounders and telehealth platforms. As of 2026, patients seeking compounded tirzepatide through most telehealth services are in legally gray territory, and the landscape may continue to evolve.

This contrasts with semaglutide, which remains on the FDA shortage list as of early 2026 — meaning compounded semaglutide retains broader legal accessibility for now.

Cost and Access

Branded Zepbound and Mounjaro list prices are approximately $1,000–$1,100 per month without insurance. Eli Lilly has introduced savings programs, including a self-pay vial program for Zepbound at significantly reduced prices for eligible patients. With commercial insurance covering anti-obesity medications, copays can drop substantially.

Medicare and Medicaid coverage of anti-obesity medications has expanded under recent policy changes but remains fragmented by state and plan type.

The Bottom Line

Tirzepatide represents a genuine leap forward in metabolic medicine. Its dual GIP/GLP-1 mechanism produces weight loss outcomes that rival bariatric surgery in some patients, with a favorable safety profile in clinical trials. The SURMOUNT-5 data confirming ~47% greater relative weight loss over semaglutide makes it the clear front-runner among approved GLP-1-class medications for weight management.

The key caveats: GI side effects are real and require a managed dose escalation, cost and insurance access remain barriers for many patients, and the compounded tirzepatide pathway has significantly narrowed following the FDA's 2025 shortage resolution. For patients who can access it — branded or through legitimate medical channels — tirzepatide is the most powerful tool currently available for medically supervised weight loss.